Glenmark gets CDSCO panel marketing nod to Remogliflozin, Teneligliptin FDC Medical Dialogues Team18 July 2021 11:30 AM ISTNew Delhi: In a major rejoice to Mumbai-based Glenmark Pharmaceuticals Limited, the Subject Expert Committee (SEC) of the Central Drugs Standard...
Dapagliflozin reduces risk of new type 2 diabetes in CKD patients: Study Medha Baranwal30 Jun 2021 9:00 AM ISTDelhi: Treatment with dapagliflozin in chronic kidney disease (CKD) patients significantly reduced the risk of new-onset type 2 diabetes (T2D), show...
Mankind Pharma launches Dapagliflozin brand Justoza for diabetes, heart failure, CKD Ruchika Sharma23 Jun 2021 1:30 PM ISTNew Delhi: Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat Diabetes, Heart Failure and Chronic...
Adjuvant Therapy with Dapagliflozin bests Insulin Dose Escalation in Diabetes: Study MD Bureau15 Jun 2021 9:00 AM ISTNearly 1 in 4 patients with type 2 diabetes mellitus eventually require insulin therapy because of progressive deterioration of glycemic control. A...
Dapagliflozin improves kidney and cardiac function in cases of FSGS kidney disease: Study Hina Zahid10 Jun 2021 9:00 AM ISTSGLT2 inhibitors offer a promising new therapeutic option in the field of nephrology and are likely to be used more extensively in future, both in...
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha Baranwal2 Jun 2021 9:30 AM ISTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular...
Abbott, AstraZeneca terminate agreement for diabetes drug Dapagliflozin in India Ruchika Sharma30 May 2021 10:15 AM ISTNew Delhi: Drug major AstraZeneca Pharma India on Friday said it has terminated its distribution agreements with Abbott Healthcare for type 2 diabetes...
Sun pharma secures trademarks rights of diabetes drug Dapagliflozin under 3 brands from AstraZeneca Ruchika Sharma29 May 2021 5:30 PM ISTNew Delhi: Drug major Sun Pharma on Friday said it has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and...
Dapagliflozin Might not Benefit Severe COVID19 Patients: DARE 19 Trial MD Bureau27 May 2021 9:00 AM ISTAlthough the primary action of sodium-glucose cotransporter-2 (SGLT2) inhibitors is on glucose and sodium reabsorption in the proximal convoluted...
Exenatide-Dapagliflozin Combo Enhances Kidney Protection: DECREASE Trial Dr Kartikeya Kohli24 May 2021 7:30 PM ISTSodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are common hypoglycemic drugs. Previous...
Dapagliflozin may Improve Diabetic Retinopathy, Finds Study MD Bureau10 May 2021 6:30 PM ISTDiabetic retinopathy (DR) is a leading cause of blindness and vision impairment. In a recent study presented at the Association for Research in Vision...
AstraZeneca Farxiga gets approval in US for CKD prevention Ruchika Sharma2 May 2021 9:30 AM ISTUK: AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of...
